Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial

BACKGROUND/AIM: DARE-19 (NCT04350593) was a randomized trial studying the effects of dapagliflozin, an SGLT2 inhibitor, in hospitalized patients with COVID-19 pneumonia and cardiometabolic risk factors. The conduct of DARE-19 offered the opportunity to define an innovative and clinically meaningful...

Descripción completa

Detalles Bibliográficos
Autores principales: Gasparyan, Samvel B., Buenconsejo, Joan, Kowalewski, Elaine K., Oscarsson, Jan, Bengtsson, Olof F., Esterline, Russell, Koch, Gary G., Berwanger, Otavio, Kosiborod, Mikhail N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196151/
https://www.ncbi.nlm.nih.gov/pubmed/35699910
http://dx.doi.org/10.1007/s43441-022-00420-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196151/
https://www.ncbi.nlm.nih.gov/pubmed/35699910
http://dx.doi.org/10.1007/s43441-022-00420-1

Ejemplares similares